GlassScriptPhysician profile
Neel Gakhar
NPI 1073977153
$2,770.31
in general payments reported to CMS, 2019-2025
23 companies · $944 in 2025
The $944 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $806 · 2024: $1,020 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.40 |
| Education | $372.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $471.70 | 2023-2025 | |
| Incyte Corporation | $355.54 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $352.50 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $258.39 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $194.35 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $171.97 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $154.85 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $107.73 | 2024-2025 | Ninlaro, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $104.97 | 2024-2025 | Libtayo |
| Seagen INC. | $93.15 | 2023-2024 | Tukysa |
| Eisai INC. | $85.17 | 2024-2025 | |
| Glaxosmithkline, LLC. | $81.72 | 2023-2025 | Zejula, Jemperli |
| Mirati Therapeutics, INC. | $69.22 | 2024 | Krazati |
| Genzyme Corporation | $52.56 | 2023-2025 | |
| Genentech USA, INC. | $38.36 | 2025 | Polivy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $32.50 | 2025 | Reblozyl |
| Beone Medicines USA, INC. | $29.88 | 2025 | Tevimbra |
| Alexion Pharmaceuticals, INC. | $23.34 | 2025 | Ultomiris |
| Myriad Genetic Laboratories, INC. | $22.90 | 2024 | Myrisk |
| Pharmaand Gmbh | $19.53 | 2025 | Rubraca |
| Puma Biotechnology, INC. | $18.57 | 2025 | |
| Servier Pharmaceuticals LLC | $15.83 | 2024 | |
| Tolmar, INC. | $15.58 | 2025 | Eligard, Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Gakhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.